These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34993032)

  • 21. Chemotherapy-induced palmer planter erythrodysesthesia.
    Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
    J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hand-foot syndrome (palmar-plantar erythrodysesthesia].
    Salzberg M; Herrmann R
    Schweiz Med Wochenschr; 2000 Oct; 130(40):1413-6. PubMed ID: 11059033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case series of docetaxel-induced dorsal hand-foot syndrome.
    Patel J; Ringley JT; Moore DC
    Ther Adv Drug Saf; 2018 Aug; 9(8):495-498. PubMed ID: 30364883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.
    Nagore E; Insa A; Sanmartín O
    Am J Clin Dermatol; 2000; 1(4):225-34. PubMed ID: 11702367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
    Hui YF; Cortes JE
    Pharmacotherapy; 2000 Oct; 20(10):1221-3. PubMed ID: 11034047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents.
    Hui YF; Giles FJ; Cortes JE
    Invest New Drugs; 2002 Feb; 20(1):49-53. PubMed ID: 12003194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
    Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
    Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Hand-foot" syndrome-an unusual case of plantar pathology presenting to a burns unit.
    Goutos I; Kaniorou-Larai M; Dziewulski P
    J Burn Care Res; 2009; 30(3):529-32. PubMed ID: 19349881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
    Ni C; Fang J; Qian H; Xu Q; Shen F
    J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
    Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
    Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
    Fabian CJ; Molina R; Slavik M; Dahlberg S; Giri S; Stephens R
    Invest New Drugs; 1990 Feb; 8(1):57-63. PubMed ID: 2345070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation.
    Dricken J; Pettke E; Griffin JA; Li HY; Mehta V
    Cureus; 2020 Apr; 12(4):e7724. PubMed ID: 32432002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
    Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
    Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.
    Arora S; Akhil R; Chacko RT; George R
    Indian J Med Paediatr Oncol; 2016; 37(2):116-8. PubMed ID: 27168711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
    Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
    Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).
    Jung S; Sehouli J; Chekerov R; Kluschke F; Patzelt A; Fuss H; Knorr F; Lademann J
    Support Care Cancer; 2017 Nov; 25(11):3545-3549. PubMed ID: 28653108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.